
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025
Description
DelveInsight’s, “Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Overview
CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137. CAR T cells may not only eradicate all cancer cells in the body, but they may remain in the body months after the infusion. T cells are white blood cells that find and fight illness and infection throughout the body. Each T cell has a receptor that can recognize antigens (proteins or molecules that are recognizable by the immune system). When the immune system recognizes foreign or abnormal antigens, it can work to destroy them. Since the initial development of CARs in 1989, CAR T-cells can be divided into four generations, according to the intracellular domain structure.
First-generation CARs comprised of the ζ (zeta) chain of complex TCR/CD3 (CD3ζ).
Second-generation CARs are characterized by the dual signal for T-cell activation one triggered by the antigen recognition and another produced by a co-stimulatory molecule, such as CD28/B7, which promotes the IL-2 synthesis to complete the activation of T-cells and avoid apoptosis.
Third-generation CARs combine sequences of co-stimulatory signals, such as OX40 (CD134), CD28, 4-1BB (CD137), CD27, DAP10, or other molecules, in combination with CD3ζ. The combination of multiple co-stimulatory signals may enhance CAR T-cell function via increased cytokine production, T-cell proliferation, and killing in the setting of recursive exposure to antigen.
Fourth Generation CARs Additionally, further optimized design of CARs, such as CAR T-cells redirected for universal cytokine killing (TRUCK), has also been suggested by many researchers. TRUCK cells produce and then release a transgenic product, such as IL-12 or IFN-γ.
Advantages of CAR-T cells includes HLA (Human Leukocyte Antigen) independent antigen recognition, Minimal risk of generating undesired autoimmunity or GvHD (Graft-versus-host disease), Significant quantities of tumor-specific T-cells are rapidly generated, CARs active in both CD4 + and CD8 + T-cells, Target antigens include proteins, carbohydrates, and glycolipids.
One of the most challenging limitations of CAR-T cell therapy is the development of tumor resistance to single antigen targeting CAR constructs. Although initially single antigen targeting CAR-T cells can deliver high response rates, the malignant cells of a significant portion of patients treated with these CAR-T cells display either partial or complete loss of target antigen expression. One of the challenges in targeting solid tumor antigens is that solid tumor antigens are often also expressed on normal tissues at varying levels. Compared to hematological malignancies, solid tumor CAR-T cell therapy is limited by the ability of CAR-T cells to traffic to and infiltrate solid tumors as the immunosuppressive tumor microenvironment and physical tumor barriers such as the tumor stroma limit the penetration and mobility of CAR-T cells.
""Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline landscape is provided which includes the disease overview and Chimeric Antigen Receptor T-Cell Therapy (CAR-T) treatment guidelines. The assessment part of the report embraces, in depth Chimeric Antigen Receptor T-Cell Therapy (CAR-T) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Emerging Drugs
Further product details are provided in the report……..
Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Therapeutic Assessment
This segment of the report provides insights about the different Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs segregated based on following parameters that define the scope of the report, such as:
Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chimeric Antigen Receptor T-Cell Therapy (CAR-T) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chimeric Antigen
Receptor T-Cell Therapy (CAR-T) drugs.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Overview
CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137. CAR T cells may not only eradicate all cancer cells in the body, but they may remain in the body months after the infusion. T cells are white blood cells that find and fight illness and infection throughout the body. Each T cell has a receptor that can recognize antigens (proteins or molecules that are recognizable by the immune system). When the immune system recognizes foreign or abnormal antigens, it can work to destroy them. Since the initial development of CARs in 1989, CAR T-cells can be divided into four generations, according to the intracellular domain structure.
First-generation CARs comprised of the ζ (zeta) chain of complex TCR/CD3 (CD3ζ).
Second-generation CARs are characterized by the dual signal for T-cell activation one triggered by the antigen recognition and another produced by a co-stimulatory molecule, such as CD28/B7, which promotes the IL-2 synthesis to complete the activation of T-cells and avoid apoptosis.
Third-generation CARs combine sequences of co-stimulatory signals, such as OX40 (CD134), CD28, 4-1BB (CD137), CD27, DAP10, or other molecules, in combination with CD3ζ. The combination of multiple co-stimulatory signals may enhance CAR T-cell function via increased cytokine production, T-cell proliferation, and killing in the setting of recursive exposure to antigen.
Fourth Generation CARs Additionally, further optimized design of CARs, such as CAR T-cells redirected for universal cytokine killing (TRUCK), has also been suggested by many researchers. TRUCK cells produce and then release a transgenic product, such as IL-12 or IFN-γ.
Advantages of CAR-T cells includes HLA (Human Leukocyte Antigen) independent antigen recognition, Minimal risk of generating undesired autoimmunity or GvHD (Graft-versus-host disease), Significant quantities of tumor-specific T-cells are rapidly generated, CARs active in both CD4 + and CD8 + T-cells, Target antigens include proteins, carbohydrates, and glycolipids.
One of the most challenging limitations of CAR-T cell therapy is the development of tumor resistance to single antigen targeting CAR constructs. Although initially single antigen targeting CAR-T cells can deliver high response rates, the malignant cells of a significant portion of patients treated with these CAR-T cells display either partial or complete loss of target antigen expression. One of the challenges in targeting solid tumor antigens is that solid tumor antigens are often also expressed on normal tissues at varying levels. Compared to hematological malignancies, solid tumor CAR-T cell therapy is limited by the ability of CAR-T cells to traffic to and infiltrate solid tumors as the immunosuppressive tumor microenvironment and physical tumor barriers such as the tumor stroma limit the penetration and mobility of CAR-T cells.
""Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline landscape is provided which includes the disease overview and Chimeric Antigen Receptor T-Cell Therapy (CAR-T) treatment guidelines. The assessment part of the report embraces, in depth Chimeric Antigen Receptor T-Cell Therapy (CAR-T) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chimeric Antigen Receptor T-Cell Therapy (CAR-T) R&D. The therapies under development are focused on novel approaches to treat/improve Chimeric Antigen Receptor T-Cell Therapy (CAR-T).
This segment of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Emerging Drugs
- Descartes-08: Cartesian Therapeutics
- CART-ddBCMA: Arcellx, Inc
- NXC-201: Nexcella, Inc
- AUTO-8: Autolus Therapeutics
- SG299: Sana Biotechnology
Further product details are provided in the report……..
Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Therapeutic Assessment
This segment of the report provides insights about the different Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
- There are approx. 180+ key companies which are developing the therapies for Chimeric Antigen Receptor T-Cell Therapy (CAR-T). The companies which have their Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drug candidates in the most advanced stage, i.e. phase II include, Cartesian Therapeutics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chimeric Antigen Receptor T-Cell Therapy (CAR-T) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chimeric Antigen
Receptor T-Cell Therapy (CAR-T) drugs.
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Report Insights
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs?
- How many Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chimeric Antigen Receptor T-Cell Therapy (CAR-T)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cartesian Therapeutics
- Arcellx, Inc
- Nexcella, Inc
- Autolus Therapeutics
- Sana Biotechnology
- Orgenesis
- CARsgen
- TILT Biotherapeutics
- Poseida Therapeutics
- Precision BioSciences
- Novartis
- Kyverna Therapeutics
- Cemacabtagene ansegedleucel
- Hrain Biotechnology
- UTC Therapeutics
- Kiromic
- Suzhou Fundamenta Therapeutics
- Gracell Biotechnology
- CARsgen
- Innovent Biologics/Nanjing IASO Biotherapeutics
- CellabMED
- Umoja Biopharma
- TC BioPharm
- ElevateBio
- Century Therapeutics
- Descartes-08
- CART-ddBCMA
- NXC-201
- AUTO-8
- SG299
- ORGCAR 19.22
- KJ-C2113
- TILT-123
- P-MUC1C-ALLO1
- PBCAR-0191
- CTL 119
- KYV 101
- Allogene Therapeutics
- HR 001
- Autologous chimeric antigen receptor T cell therapy
- Gamma delta chimeric antigen receptor T-cell therapy
- ThisCART 19 A
- AZD 0120
- CT 071
- Equecabtagene autoleucel
- CLM 202
- UB VV310
- CAR-T cell therapy
- Research programme: CAR-T cell therapies
- CNTY 108
Please Note: It will take 4-5 business days to complete the report upon order confirmation.
Table of Contents
450 Pages
- Introduction
- Executive Summary
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) : Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Descartes-08: Cartesian Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- NXC-201: Nexcella, Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- SG299: Sana Biotechnology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Products
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Unmet Needs
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Market Drivers and Barriers
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Future Perspectives and Conclusion
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Analyst Views
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.